Accepted Manuscript

Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity

Friedrich Hahn, Corina Hutterer, Christophe Henry, Stuart T. Hamilton, Hanife Strojan, Alexandra Kraut, Ulrike Schulte, Martin Schütz, Stephan Kohrt, Christina Wangen, José Pfizer, Yohann Couté, William D. Rawlinson, Stefan Strobl, Manfred Marschall

PII: S0166-3542(18)30390-5

DOI: 10.1016/j.antiviral.2018.09.012

Reference: AVR 4375

To appear in: Antiviral Research

Received Date: 21 June 2018

Revised Date: 21 September 2018

Accepted Date: 26 September 2018

Please cite this article as: Hahn, F., Hutterer, C., Henry, C., Hamilton, S.T., Strojan, H., Kraut, A., Schulte, U., Schütz, M., Kohrt, S., Wangen, C., Pfizer, José., Couté, Y., Rawlinson, W.D., Strobl, S., Marschall, M., Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity, *Antiviral Research* (2018), doi: https://doi.org/10.1016/j.antiviral.2018.09.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity

Friedrich Hahn^{a*}, Corina Hutterer^{a*}, Christophe Henry^{b,e*}, Stuart T. Hamilton^c, Hanife Strojan^a, Alexandra Kraut^d, Ulrike Schulte^a, Martin Schütz^a, Stephan Kohrt^a, Christina Wangen^a, José Pfizer^b, Yohann Couté^d, William D. Rawlinson^c, Stefan Strobl^{b,e} and Manfred Marschall^{a#}
*These authors contributed equally to the study.

Affiliations: ^aInstitute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany; ^b4SC AG, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany; ^cSerology and Virology Division, SEALS Microbiology Prince of Wales Hospital Randwick, School of Women's and Children's Health, School of Medical Sciences, School of Biotechnology and Biomolecular Sciences, University of NSW, Sydney, Australia; ^dUniversity Grenoble Alpes, CEA, INSERM, BIG-BGE, F-38000 Grenoble, France; ^eCurrent address: BioNTech Small Molecules GmbH, Am Klopferspitz 19a, 82152 Planegg-Martinsried, Germany.

*Corresponding author: Prof. Dr. Manfred Marschall, Schlossgarten 4, 91054 Erlangen, Germany, e-mail manfred.marschall@fau.de

Keywords: Human cytomegalovirus; antiviral compounds; experimental drug development; drug immobilization by linker coupling; mass spectrometry-based target identification; biological properties and mode of action.

Download English Version:

https://daneshyari.com/en/article/11025747

Download Persian Version:

https://daneshyari.com/article/11025747

<u>Daneshyari.com</u>